Tempus AI is trading up 4.34% at $87.18; no specific reason is confirmed.
- In the prior session, shares rose 9.03% to close at $83.55.
- An October 6 report noted FDA 510(k) clearance for Tempus ECG-MR, an AI tool for early mitral regurgitation detection; it did not link the clearance to the gain.
- No separate October 6 company announcement or clear catalyst was identified. Supplied index gains were below 0.5%, insufficient to attribute the move to broad market sentiment.